Paradromics Reports Four Years of Stable Neural Recording for Connexus Brain-Computer Interface

Austin-based neurotechnology company Paradromics Inc. announced on October 8, 2026 via AdvaMed that its Connexus brain-computer interface (BCI) cortical electrode modules demonstrated more than four years of stable in-vivo neural recording and decoding performance without electrode migration.

According to Paradromics founder and CEO Matt Angle, PhD, and VP of Neuroscience Shaoyu Qiao, PhD, two preclinical sheep implanted with cortical modules representative of the Connexus BCI maintained stable spike signal-to-noise ratios (SNR) across a four-year follow-up period, while a separate six-animal study of the full implantable Connexus platform has maintained stable spike SNR for nearly two years. The system uses penetrating microwires thinner than a human hair to capture single-neuron resolution signals while minimizing tissue reaction.

Paradromics Chief Medical Officer Stephen Ryu, MD, noted that multi-year implant durability is essential to avoid repeat neurosurgeries as the company advances its Connect-One Early Feasibility Study (EFS) evaluating the Connexus BCI in human patients with severe speech and motor impairments.